Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT01874054
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Saint Francis Hospital / Bon Secours, Greenville, South Carolina, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT01871675
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Oklahoma University, Oklahoma City, Oklahoma, United States
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT01832922
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 523
- Registration Number
- NCT01776840
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 36
- Registration Number
- NCT01754857
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Cristina Gasparetto
- Target Recruit Count
- 56
- Registration Number
- NCT01754402
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 475
- Registration Number
- NCT01732926
- Locations
- 🇨🇦
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
🇮🇹Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 743
- Registration Number
- NCT01724021
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01716806
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Cantonal Hospital of St. Gallen
- Target Recruit Count
- 50
- Registration Number
- NCT01701076
- Locations
- 🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.